ParagonRx® | Minimize Risk and Optimize Use

Japan's largest drugmaker Takeda Pharmaceutical Co (4502.T) said it resubmitted two new drug applications (NDA) to the U.S. Food and Drug Administration (FDA) for investigational type 2 diabetes therapies.

The applications were for alogliptin and the fixed-dose combination alogliptin/pioglitazone, the company said.

Takeda said the FDA will review the NDA resubmissions within the next six months.

Shares of the company closed at 3,735 yen on the Tokyo Stock Exchange on Monday.

[Link]